Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SciSparcSPRC -2.21%39 12-1 Month Momentum % is -86.93% as of Aug. 28, 2026. GuruFocus rates SPRC with a GF Score™ of 39/100 and a GF Value™ of $3.03 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,356 Biotechnology companies, SciSparc ranks worse than 94.76% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-28), SciSparc's 12-1 Month Momentum % is -86.93%.
The industry rank for SciSparc's 12-1 Month Momentum % or its related term are showing as below:
SPRC's 12-1 Month Momentum % is ranked worse than 94.76% of 1356
companies
in the Biotechnology industry
Industry Median: -21.57
vs SPRC: -86.93
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
SciSparc 12-1 Month Momentum % Related Terms
SPRC vs ACUT, ONCO, PPCB: 12-1 Month Momentum % Comparison
For the Biotechnology subindustry, SciSparc's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SciSparc 12-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SciSparc's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where SciSparc's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 12-1 Month Momentum % of -86.93% mean?
SciSparc (SPRC) has a 12-1 Month Momentum % of -86.93% as of Aug. 28, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on SciSparc and its competitors. According to the industry distribution chart, SciSparc ranks #1285 out of 1356 companies in the Biotechnology industry, placing it in the top 94.8%.
Is SciSparc's 12-1 Month Momentum % too high?
SciSparc's current 12-1 Month Momentum % is -86.93%. Based on the distribution chart, SciSparc ranks #1285 out of 1356 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SciSparc has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SciSparc's 12-1 Month Momentum % compare to ACUT and ONCO?
According to the Biotechnology industry distribution chart, SciSparc ranks #1285 out of 1356 companies for 12-1 Month Momentum %. This places SciSparc in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on SciSparc and its competitors. SciSparc's current 12-1 Month Momentum % is -86.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SciSparc stock overvalued right now?
Based on GuruFocus' analysis, SciSparc (SPRC) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.03, compared to a current price of $6.50 — trading 114.6% above its estimated fair value. The current 12-1 Month Momentum % is -86.93%. SciSparc's overall GF Score™ is 39/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For SciSparc (SPRC), the current 12-1 Month Momentum % is -86.93% as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SciSparc (SPRC) Overvalued in 2026?
Based on GuruFocus' analysis, SciSparc stock appears to be overvalued.
The current stock price of $6.50 is trading 114.6% above its estimated GF Value™ of $3.03.
GuruFocus considers SciSparc to be Significantly Overvalued.
Key valuation signals for SPRC:
12-1 Month Momentum %: -86.93%
GF Value™: $3.03 vs. price of $6.50 (114.6% above fair value)
No single metric tells the full story. See the SPRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two operating reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
39GF Score
Get the complete analysis for SPRC
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRC has been successfully added to your 
